Telesis Bio Partners With Danaher Company Beckman Coulter
Danaher Unusual Options Activity
Integrated DNA Technologies Unveils New Lymphoma Panel to Enhance Blood Cancer Research
Danaher Schedules Third Quarter 2024 Earnings Conference Call
Beckman Coulter and Scopio Labs Add World's First Digital Bone Marrow Imaging and Analysis to Long-Term Partnership
Is It Too Late To Consider Buying Danaher Corporation (NYSE:DHR)?
Don't Miss These Investor Days in September. How to Trade Them with Options
Deutsche Bank Raises Price Target on Danaher to $285 From $270
Danaher To Go Ex-Dividend On September 27th, 2024 With 0.27 USD Dividend Per Share
Danaher Keeps Quarterly Dividend at $0.27 a Share, Payable Oct. 25 to Shareholders of Record Sept. 27
Press Release: Danaher Announces Quarterly Dividend
Unpacking the Latest Options Trading Trends in Danaher
$1000 Invested In Danaher 10 Years Ago Would Be Worth This Much Today
Express News | RBC Capital Reiterates Outperform on Danaher, Maintains $300 Price Target
A Quick Look at Today's Ratings for Danaher(DHR.US), With a Forecast Between $275 to $310
Jefferies Sticks to Its Buy Rating for Danaher (DHR)
Smart Money Is Betting Big In DHR Options
Integrated DNA Technologies Bolsters Comprehensive Genomic Profiling Solutions With Launch of New Archer HRD Technology for Cancer Research
Wells Fargo Maintains Danaher(DHR.US) With Hold Rating, Maintains Target Price $280
Danaher Still Expects Adj Core Rev Down Low-Single Digits Yr-over-Yr for 3Q, FY24 >DHR